Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal CRJIM (Clinical and Research Journal in Internal Medicine) Jurnal Penyakit Dalam Indonesia
Machsoos, Budi Darmawan
Unknown Affiliation
Education Health Professions Immunology & microbiology Medicine & Pharmacology Nursing Public Health Other

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
The Effect of Vitamin E on Oral Mucositis Induced by Chemotherapy in Non-Hodgkin Lymphoma Patients Receiving Chemotherapy Hermanto, Djoko Heri; Habsari, Indri; Machsoos, Budi Darmawan
Clinical and Research Journal in Internal Medicine Vol 1, No 2 (2020): New: The Second Issue is Coming!
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.crjim.2020.001.02.5

Abstract

Chemotherapy-induced mucositis is a side effect of chemotherapy that often occurs in patients with solid tumors and lymphoma. Oral mucositis can affect nutritional status and the risk of infection, both local and systemic. Antioxidant Vitamin E is beneficial for the prevention and therapy of both oral and gastrointestinal mucositis. Aim: To determine the effect of vitamin E therapy on the incidence of oral mucositis in non-Hodgkin lymphoma (NHL) patients receiving chemotherapy. Methods: This is a single-blind experimental study in 62 NHL patients undergoing chemotherapy who meet the inclusion criteria. Patients who met the inclusion criteria were randomly divided into 2 groups, namely 31 patients (treatment group) received vitamin E 400 mg / IU per day for 7 days and 31 patients in the placebo group. The incidence and grade of oral mucositis were observed on day 7. Statistical analysis used Chi-Square and Mann Whitney test according to the data type. Results: a total of 67% NHL patients were male, most of whom were over 46 years of age and as many as 50% of patients used chemotherapy regimens RCHOP and CHOP. There was an incidence of oral mucositis in 35% in the placebo group and 12.9% in the treated group (p = 0.038). In the placebo group, there were 4.8% of patients with grade 2 and 3 oral mucositis, which was not found in the therapy group. Conclusion:  treatment with vitamin E in NHL patients undergoing chemotherapy can prevent chemotherapy-induced oral mucositis and prevent its severity.
Comparison of Socal Score and Hasford Score Against the Response of Imatinib Mesylate Therapy in Patients with Chronic Granulocytic Leukemia in dr. Saiful Anwar Hospital Malang Somarnam, Somarnam; Machsoos, Budi Darmawan; Hermanto, Djoko Heri
Jurnal Penyakit Dalam Indonesia Vol. 6, No. 4
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Introduction. The Socal and Hasford scores developed before the era of tirosine kinase inhibitor (TKI) therapy to provide predictions and prognosis for the results of therapy for chronic myeloid leukemia patients (CML). Until now the superiority of Socal and Hasford scores is still debated in predicting the results of therapy in the era of TKI. Imatinib mesylat is a first line TKI in the treatment of CML. This study aims to determine the superior predictive score in predicting hematological and molecular response of patients treated with imatinib mesylate. Methods. A survey study was conducted with data taken retrospectively from medical records. Subjects were chronic phase LGK patients who had at least been given imatinib mesylate therapy for 12 months. Calculation of Socal and Hasford scores was carried out based on patient data when first receiving Imatinib. To see the difference in distribution between the two scores, a marginal homogeneity statistic was used. To see the process of changing the response of patients treated with Imatinib, a suitability test using chi-square and Fischer was conducted with a significant p value, p 0,05. Conclusion. There was no significant difference between Hasford and Socal scores in predicting hematological responses and molecular responses of chronic CML patients. Socal scores and Hasford scores can be used to predict hematological and molecular responses in chronic CML patients treated with imatinib mesylate.
Co-Authors Habsari, Indri Hermanto, Djoko Heri Somarnam, Somarnam